Eli Lilly and Company $LLY Stock Holdings Lessened by Laurel Wealth Advisors LLC

Posted by Francis Steltz on Oct 31st, 2026

Eli Lilly and Company logo Laurel Wealth Advisors LLC decreased its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 3.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 13,556 shares of the company’s stock after selling 501 shares during the quarter. Eli Lilly and Company makes up 1.5% of Laurel Wealth Advisors LLC’s investment portfolio, making the stock its 14th largest position. Laurel Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $15,685,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of LLY. Bank of America Corp DE bought a new stake in shares of Eli Lilly and Company in the second quarter worth about $13,522,666,000. Jupiter Topco LLC bought a new position in Eli Lilly and Company during the 2nd quarter valued at approximately $4,667,180,000. Fifth Third Bancorp raised its position in Eli Lilly and Company by 321.3% during the 1st quarter. Fifth Third Bancorp now owns 1,963,490 shares of the company’s stock valued at $1,805,959,000 after purchasing an additional 1,497,423 shares during the last quarter. Corient Private Wealth LP bought a new position in Eli Lilly and Company during the 2nd quarter valued at approximately $764,116,000. Finally, BlackRock Inc. lifted its holdings in Eli Lilly and Company by 1.6% in the 2nd quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock worth $81,009,981,000 after buying an additional 1,046,558 shares during the period. 82.53% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the stock in a transaction on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the completion of the transaction, the executive vice president owned 11,875 shares in the company, valued at approximately $14,131,250. This represents a 29.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the firm’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the transaction, the executive vice president directly owned 54,147 shares of the company’s stock, valued at $63,628,139.70. This represents a 10.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,500 shares of company stock valued at $15,958,170 over the last ninety days. Company insiders own 0.14% of the company’s stock.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $1,415.64 on Friday. The stock’s 50 day simple moving average is $1,197.72 and its two-hundred day simple moving average is $1,092.57. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. The stock has a market cap of $1.33 trillion, a price-to-earnings ratio of 45.95, a PEG ratio of 1.73 and a beta of 0.46. Eli Lilly and Company has a fifty-two week low of $834.19 and a fifty-two week high of $1,449.68.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last posted its earnings results on Thursday, October 29th. The company reported $7.48 earnings per share for the quarter, topping analysts’ consensus estimates of $5.71 by $1.77. Eli Lilly and Company had a return on equity of 93.68% and a net margin of 31.90%. The firm had revenue of $24.40 billion for the quarter, compared to the consensus estimate of $22.58 billion. During the same quarter in the prior year, the business earned $7.02 EPS. The business’s revenue for the quarter was up 38.6% on a year-over-year basis. As a group, analysts expect that Eli Lilly and Company will post 35.50 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Friday, November 13th. Eli Lilly and Company’s dividend payout ratio is presently 23.22%.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

Positive Sentiment: Q3 results substantially beat expectations. Revenue rose 39% year over year to $24.4 billion, while adjusted EPS was $7.48 versus the $5.68 consensus estimate. Mounjaro sales increased 65% to $10.7 billion and Zepbound sales rose 49% to $5.35 billion. Lilly third-quarter results
Positive Sentiment: Lilly raised its 2026 revenue forecast to $91 billion-$92 billion, up from $85 billion-$87 billion previously. Strong demand, broader Medicare access and growing middle-income adoption are supporting expectations for continued GLP-1 expansion. Q3 earnings call highlights
Positive Sentiment: Analysts raised their price targets and maintained bullish ratings. Scotiabank lifted its target to $1,605 with a “sector outperform” rating, Morgan Stanley raised its target to $1,596 with an “overweight” rating, and RBC moved to $1,600 with an “outperform” rating. Analyst commentary
Positive Sentiment: Pipeline and portfolio diversification offer additional upside. Positive Phase 3 retatrutide data strengthened Lilly’s competitive position against Novo Nordisk, while oncology, immunology and neuroscience products are beginning to contribute more meaningfully. Lilly growth opportunities
Negative Sentiment: Investors face execution and valuation risks. Realized prices fell 15%, meaning volume growth must continue to offset pricing pressure. Results also benefited from roughly $900 million in one-time items, and acquired in-process research charges weighed on earnings. With GLP-1 drugs representing a large share of revenue and the stock near its high, expectations are elevated. Reuters earnings report

Analyst Ratings Changes

A number of brokerages have recently weighed in on LLY. Berenberg Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating and set a $1,400.00 price objective on the stock in a research report on Tuesday, September 15th. Scotiabank upped their target price on Eli Lilly and Company from $1,300.00 to $1,605.00 and gave the company a “sector outperform” rating in a report on Friday. Morgan Stanley raised their price target on Eli Lilly and Company from $1,430.00 to $1,596.00 and gave the stock an “overweight” rating in a research note on Friday. The Goldman Sachs Group reiterated a “buy” rating and issued a $1,413.00 price target on shares of Eli Lilly and Company in a report on Tuesday, October 20th. Finally, Truist Financial reiterated a “buy” rating and issued a $1,612.00 price target (up from $1,376.00) on shares of Eli Lilly and Company in a report on Friday. One analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average target price of $1,398.43.

Read Our Latest Analysis on Eli Lilly and Company

Eli Lilly and Company Company Profile

(Free Report)

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.